Recognition of this dual BCL-2/BCL-xL dependence has prompted several ALL trials combining venetoclax with low-dose navitoclax to enhance therapeutic efficacy without the dose-limiting thrombocytopenia associated with navitoclax monotherapy (NCT03181126, NCT05192889). Here, BCL2L1 is linked to acute lymphoblastic leukemia.